Alnylam Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration and Submits Marketing Authorization Application to the European Medicines Agency for L...
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Business Wire
- Lumasiran is the First Potential Therapeutic to Demonstrate Substantial Reduction in Urinary Oxalate Excretion – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO), in development for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is an ultra-rare, life-threatening disease impacting the kidneys and other vital organs; it affects infants, children, and adults.In the U.S., lumasiran has previously received Pediatric Rare Disease Designation, Orphan Drug Designation, and Breakthrough Therapy Designation for the treatment of PH1, based on data showing a substantial reduction in urinary oxalate, the key toxic metabolite responsible for the clinical manifestations of the disease.The Company
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at Freedom Capital from a "hold" rating to a "strong-buy" rating.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $510.00 price target on the stock.MarketBeat
- Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Canaccord Genuity Group Inc. from $415.00 to $429.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 2/12/26 - Beat
ALNY
Sec Filings
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- ALNY's page on the SEC website